Seed Displacements after Permanent Brachytherapy for Prostate Cancer in Dependence on the Prostate Level

Pinkawa, Michael; Gagel, Bernd; Asadpour, Branka; Piroth, Marc D.; Klotz, Jens; Borchers, Holger; Jakse, G.; Eble, Michael J.

doi:10.1007/s00066-008-1886-3

Cited by 22 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two BT modalities are used for prostate cancer: permanent implantation with low-dose-rate (LDR) seeds using 125 I or 103 Pd isotopes [3,32,34,35,41], and temporary implantation with high-dose-rate (HDR) or pulsed-dose-rate (PDR) technique using 192 Ir isotope [1, 2, 8-10, 18, 21, 25, 30, 39, 43].…”

Section: Introductionmentioning

confidence: 99%

“…Intensity-modulated radiotherapy (IMRT) and image-guided radiation therapy (IGRT) are widely used treatment techniques [36,42]. In brachytherapy (BT), the safety margin can be completely omitted, since the planning target volume (PTV) is equal to the clinical target volume (CTV), and a higher degree of protection of organs at risk (OARs) can be reached because of the smaller treated volume [17].Two BT modalities are used for prostate cancer: permanent implantation with low-dose-rate (LDR) seeds using 125 I or 103 Pd isotopes [3,32,34,35,41], and temporary implantation with high-dose-rate (HDR) or pulsed-dose-rate (PDR) technique using 192 Ir isotope [1, 2, 8-10, 18, 21, 25, 30, 39, 43].The treatment protocol for intermediate-and high-risk, clinically nonmetastatic prostate cancer at our institution includes the combination of three-dimensional conformal RT and BT boost using HDR afterloading technique with 192 Ir source.The purpose of the present study is to quantitatively evaluate the dose distributions of prostate HDR-BT implants regarding dose conformity, homogeneity, and dose to OARs. …”

mentioning

confidence: 99%

See 1 more Smart Citation

Dosimetric Evaluation of High-Dose-Rate Interstitial Brachytherapy Boost Treatments for Localized Prostate Cancer

et al. 2010

View full text Add to dashboard Cite

US-based treatment plans for HDR prostate implants based on the real positions of catheters provided acceptable dose distributions. In the majority of the cases, the doses to urethra and rectum were kept below the defined tolerance levels. For rectum, the dose in reference points correlated well with dose-volume parameters. For urethra dose characterization, the use of D1 volumetric parameter is recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Dosimetric Evaluation of High-Dose-Rate Interstitial Brachytherapy Boost Treatments for Localized Prostate Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…It is estimated that more than 50,000 patients with clinically localized prostate cancer are treated with 125 I or 103 Pd seeds every year worldwide and this number is anticipated to increase in the near future [1,4,6,9,11,[14][15][16][17]21]. Furthermore, stereotactically guided interstitial therapy with 125 I is an established and important therapeutic option in the treatment of gliomas and brain metastases [19,20].…”

Section: Introductionmentioning

confidence: 99%

Radiation Protection of Persons Living Close to Patients with Radioactive Implants

Kaulich¹,

Bamberg²

2010

Strahlenther Onkol

View full text Add to dashboard Cite

Background: Permanent interstitial brachytherapy is -in certain cases -a very successful therapeutic option, but application of radioactive implants always results in only gradually diminishing radiation exposure of persons in the patient's immediate surroundings. Material and Methods: Using patients with clinically localized prostate cancer treated with iodine-125 ( 125 I) or palladium-103 ( 103 Pd) as an example, it is shown how a patient, if necessary or wished by him, can, by wearing commercially available X-ray protection shorts, reduce radiation exposure of family members in such a way that at a distance r from the patient a given dose per year is not exceeded. Results: The computational procedures necessary for the determination of the individual periods of wearing X-ray protection clothing are provided in the form of formulae and graphics. All considerations and calculations can also be applied to other radiotherapeutic interventions involving the use of 125 I, 103 Pd or other γ-sources. Conclusion: If necessary, a patient with permanent radioactive implants can reduce radiation exposure of family members by wearing special X-ray protection clothing for a limited period of time. This kind of radiation protection is very efficient and considerably simpler to accomplish than a reduction of exposure time or an increase of the distance between the patient and family members. Strahlenschutz von Personen, die mit Patienten mit radioaktiven Implantaten zusammenlebenHintergrund: Die permanente interstitielle Brachytherapie ist eine sehr erfolgreiche therapeutische Option, die aber immer auch mit einer Strahlenexposition von Personen in unmittelbarer Umgebung des Patienten verbunden ist. Material and Methodik: Am Beispiel von Patienten mit Prostatakarzinom, die mit Jod-125 ( 125 I) oder Palladium-103 ( 103 Pd) behandelt wurden, wird gezeigt, wie der Patient durch individuell begrenzte Tragedauer kommerziell erhältlicher Strahlenschutzhosen die Strahlenexposition seiner Familienmitglieder, falls erforderlich oder von ihm gewünscht, so limitieren kann, dass im Abstand r vom Patienten eine vorgegebene Dosis pro Jahr nicht überschritten wird. Ergebnisse: Die benötigten Berechnungsgrundlagen werden als Formeln und Grafiken zur Bestimmung der individuellen Tragedauer der Strahlenschutzhosen präsentiert. Alle Überlegungen und Berechnungen lassen sich auch auf andere strahlentherapeutische Maßnahmen mit 125 I, 103 Pd oder auch andere γ-Strahler anwenden. Schlussfolgerung: Ein Patient mit radioaktivem Permanentimplantat kann durch das zeitlich begrenzte Tragen von Strahlenschutzhosen die Strahlenexposition von Familienmitgliedern stark reduzieren. Diese Strahlenschutzmaßnahme ist sehr wirkungsvoll und wesentlich einfacher anzuwenden als eine Reduktion der Aufenthaltsdauer oder eine Vergrößerung des Abstands zu Familienmitgliedern. Schlüsselwörter: Brachytherapie · Seedimplantation · 125 I · 103 Pd · Strahlenschutz IntroductionThe use of radioactive implants (iodine-125 [ 125 I] or palladium-103 [ 103 Pd] seeds) has been in...

show abstract

“…The distance between the side of the index finger and the seeds is therefore markedly less than 1 mm at such times. Since this procedure relies a great deal on "feeling" [16,22], the treating physician does not wear lead gloves. These would impede sensitivity and lengthen the duration of the application, and in turn increase the exposure to radiation [1,9,25].…”

Section: Methodsmentioning

confidence: 99%

Exposure of Treating Physician to Radiation during Prostate Brachytherapy Using Iodine-125 Seeds

et al. 2009

View full text Add to dashboard Cite

Background and Purpose: Only sparse reports have been made about radiation exposure of the treating physician during prostate seed implantation. Therefore, thermoluminescence dosimeter (TLD) measurements on the index fingers and the backs of both hands were conducted. Material and Methods: Stranded iodine-125 seeds with a mean apparent activity of 27.4 MBq per seed were used. During application, the treating physician manipulated the loaded needle with the index fingers, partially under fluoroscopic control. Four physicians with varying experience treated 24 patients. The radiation exposure was determined with TLD-100 chips attached to the index fingertips and the backs of hands. Radiation exposure was correlated with the physician's experience.

show abstract

Seed Displacements after Permanent Brachytherapy for Prostate Cancer in Dependence on the Prostate Level

Abstract: The largest prostate tissue and seed displacements were observed at the prostate base, associated with an implant compression. Predominantly inferior and posterior displacements implicate consequential smaller preplanning margins at the apex and the posterior prostate.

Cited by 22 publications

References 38 publications

Dosimetric Evaluation of High-Dose-Rate Interstitial Brachytherapy Boost Treatments for Localized Prostate Cancer

Dosimetric Evaluation of High-Dose-Rate Interstitial Brachytherapy Boost Treatments for Localized Prostate Cancer

Radiation Protection of Persons Living Close to Patients with Radioactive Implants

Exposure of Treating Physician to Radiation during Prostate Brachytherapy Using Iodine-125 Seeds

Contact Info

Product

Resources

About